Get the Stockscreener App
2.10
7.69%
0.15
After Hours:
2.05
-0.05
-2.38%
Biovie Inc stock is traded at $2.10, with a volume of 160.87K.
It is up +7.69% in the last 24 hours and up +31.25% over the past month.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
See More
Previous Close:
$1.95
Open:
$1.99
24h Volume:
160.87K
Relative Volume:
1.36
Market Cap:
$15.84M
Revenue:
-
Net Income/Loss:
$-19.92M
P/E Ratio:
-0.4916
EPS:
-4.2716
Net Cash Flow:
$-20.51M
1W Performance:
+4.48%
1M Performance:
+31.25%
6M Performance:
+51.08%
1Y Performance:
+118.75%
1-Day Range:
$1.92
$2.20
1-Week Range:
$1.907
$2.29
52-Week Range:
$1.06
$9.56
Biovie Inc Stock (BIVI) Company Profile
Name
Biovie Inc
Sector
Industry
Phone
775-888-3162
Address
680 W NYE LANE, CARSON CITY
Compare BIVI vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIVI
Biovie Inc
|
2.10 | 14.63M | 0 | -19.92M | -20.51M | -4.2716 |
VRTX
Vertex Pharmaceuticals Inc
|
529.59 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
649.81 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
916.80 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.04 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.99 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biovie Inc Stock (BIVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-15-21 | Initiated | B. Riley Securities | Buy |
Biovie Inc Stock (BIVI) Latest News
BioVie Inc. Class A Financial Disclosures & SEC Filings - TradingView
[EFFECT] BIOVIE INC. SEC Filing - Stock Titan
BioVie Inc. Class A Actuals & Estimates (NASDAQ:BIVI) - TradingView
BioVie | 4: Statement of changes in beneficial ownership of securities-Officer DO CUONG V - Moomoo
BIVI Forecast — Price Target — Prediction for 2027 - TradingView
BioVie Inc (BIVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Biovie Files To Offer Up To $300 Million In SecuritiesSEC Filing - TradingView
BioVie (NASDAQ: BIVI) files $300M shelf registration to sell securities - Stock Titan
BioVie Inc (BIVI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BioVie Inc (BIVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioVie Inc (BIVI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BioVie Inc (BIVI) Institutional Confidence - TradingKey
BioVie Inc (BIVI) Valuation: PE, PB & Fair Value Analysis - TradingKey
BioVie Inc (BIVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BioVie Inc (BIVI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BioVie Inc (BIVI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BIVI Q1 2026 Earnings: EPS Beat Driven by Lower-than-Expected Operating ExpensesAdjusted Earnings Analysis - newsline.com
BIVI Q1 2026 Earnings: Narrower Loss Than Expected as Pipeline Progress ContinuesEnergy Earnings Report - newsline.com
BIVI Q1 2026 Earnings: EPS Beat Amid Clinical Progress; Stock DeclinesShare Repurchase Impact - newsline.com
Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareh - GuruFocus
Law firm investigates BioVie officers for possible breach of duties to shareholders - Pluang
BioVie Inc. (BIVI) Q1 2026 Earnings: EPS Surpasses Estimates Despite Ongoing Revenue VoidEarnings Call Highlights - newsline.com
BIVI Q1 2026 Earnings: Narrower-Than-Expected Loss but Stock Declines on No Revenue StreamTrough Earnings Signal - newsline.com
Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Barchart.com
Is BioVie's Bezisterim Poised for a Breakthrough in Neurodegenerative Diseases - Kavout | AI
BIVI: Imminent clinical data for Parkinson's and long COVID could unlock major commercial opportunities - TradingView
BioVie Deadline Alert - TMX Newsfile
BioVie Inc. Warrant (BIVIW) Holds Steady Near Support – Waiting for a CatalystProfitability Factor - newsline.com
BIVI Q1 2026 Earnings: Narrower Loss than Expected as Clinical Pipeline AdvancesTrough Earnings Signal - newsline.com
BioVie: Long COVID trial fully enrolled – ICYMI - Yahoo Finance
Foremost Clean Energy and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
BioVie Inc. (BIVI) Hovers Near Key Support Levels as Stock Remains FlatAdvance Decline Line - The Legal Advocate
Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2 - Weekly Voice
BioVie to highlight neuro and liver disease programs in June 2 investor webinar - Proactive financial news
BioVie Inc. (BIVI) Declines 5.26%, Testing Key Support Near $1.37Dealer Gamma - The Legal Advocate
BioVie Inc. (BIVI) Declines 5.26%, Testing Critical Support Near $1.37BPI Bear Confirmed - The Legal Advocate
BIVI Q1 2026 Earnings: EPS Beats Estimates Despite No Revenue, Stock DropsEstimate Accuracy - The Legal Advocate
Small cap wrap: First Phosphate, Miivo Holdings, 1911 Gold, BioVie… - Proactive financial news
BioVie completes enrollment in Long COVID trial as need for treatments grows - Proactive financial news
BioVie Inc. (BIVI) Faces Selling Pressure as Shares Slide 5.9%Momentum Trade - The Legal Advocate
BioVie (BIVI) Completes Enrollment for Phase 2 Trial of Bezister - GuruFocus
BioVie completes enrollment in Phase 2 Long COVID trial - Yahoo! Finance Canada
BioVie completes enrollment in Long COVID treatment trial - Investing.com
BioVie completes enrollment in Long COVID treatment trial By Investing.com - Investing.com Nigeria
BIVIBioVie Inc Stock Price and Quote - Finviz
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID - The Manila Times
BioVie Announces Full Enrollment of the ADDRESS-LC Trial of - GlobeNewswire
Biovie Inc Stock (BIVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):